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Ex vivo treatment of patient 
biopsies as a novel method 
to assess colorectal tumour 
response to the MEK1/2 inhibitor, 
Selumetinib
Sonia M. Novo1, Stephen R. Wedge2 & Lesley A. Stark1
Although an array of new therapeutics has emerged for the treatment of colorectal cancer, their use is 
significantly impacted by variability in patient response. Better pre-clinical models could substantially 
improve efficacy as it may allow stratification of patients into the correct treatment regime. Here 
we explore acute, ex vivo treatment of fresh, surgically resected human colorectal tumour biopsies 
as a novel pre-clinical model for identifying patient response to specific therapeutics. The MEK1/2 
inhibitor, Selumetinib (AZD6244, ARRY-142886) was used as a tool compound. Firstly, we established 
an acute treatment protocol and demonstrated this protocol could differentiate phenotypic and 
pharmacodynamic responses to Selumetinib (0–3uM). We then used the protocol to evaluate 
Selumetinib response in tumours from 23 colon cancer patients. These studies revealed that the agent 
inhibited pERK1/2 phosphorylation in all tumours, caused a significant decrease in proliferation in 
5/23 (22%) tumours, and that KRAS/BRAF mutant tumours were particularly sensitive to the anti-
proliferative effects of the agent. These data are consistent with data from clinical trials of Selumetinib, 
suggesting that acute treatment of small tumour biopsies is worthy of further exploration as a pre-
clinical model to evaluate colorectal cancer response to novel therapies.
Colon cancer remains a major cause of morbidity and mortality worldwide with one million diagnoses annually 
and at best, 60% survival1. Standard chemotherapy is associated with severe side effects and provides marginal 
benefit to the majority of patients2. Hence, there is an overwhelming need for novel, more targeted therapies that 
would impact on disease progression and patient outcomes.
A major impediment to progress in the development and use of targeted therapies for colorectal cancer is 
the lack of good pre-clinical models that can accurately predict the efficacy of new drugs and determine the 
patient population most likely to benefit3. Ideally, models should conserve the heterogeneity observed in patient 
tumours with respect to architecture, cell types (cancer and stromal) and tumour microenvironment. Traditional 
preclinical models of colorectal cancer, including tumour cell lines, genetically modified animals and cell line 
derived tumour xenografts, failed to capture this heterogeneity resulting in poor mapping to clinical outcomes4,5. 
Organoids derived from human tumours have recently gained traction as a representative model for colorectal 
cancer6–8. However, organoids do not recapitulate the heterogenous architecture of human cancers or model 
tumour-stromal interactions. Furthermore, the growth selection pressures applied during organoid generation 
has the potential to introduce bias. Another approach that is considered more representative is the use of patient 
derived xenografts (PDX), where a small fragment from a patient tumour biopsy is implanted either subcutane-
ously or orthotopically into an immunodeficient mouse9,10. However, the timescales and costs involved in this 
process are very significant. Development of alternative, innovative approaches for identifying tumours that will 
respond to specific agents is now essential if new therapies are to be targeted to the correct patient population.
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Ex-vivo culture of intact tumour biopsies is potentially an extremely attractive system for analysing patient 
response to therapeutics as tumour architecture is retained, spatial relationships between tumour and stroma 
preserved, and the unique genetic and epigenetic modifications in each individual tumour incorporated11–13. 
Furthermore, biopsies from individual patients can be rapidly investigated. Supporting the validity of this model 
system, Vaira et al. demonstrated that vibrotome cut tumour sections grown in ex vivo culture are stable over time 
and exhibit the expected signalling response to PI3K inhibitors14. Furthermore, Rubio et al.15 demonstrated that 
the ex vivo response of fine needle pancreatic cancer biopsies to anti-cancer agents predicted the effects of the 
agents in vivo15.
Here we used the MEK1/2 inhibitor, Selumetinib (AZD6244, ARRY-142886) as a model therapeutic to test ex 
vivo treatment of fresh, colorectal tumour biopsies as a method to determine patient sensitivity to new therapies. 
The RAS/RAF-MEK1/2-ERK1/2 signalling cascade is deregulated in approximately 50% of colorectal tumours, 
which drives tumour progression through constitutive ERK1/2 activity16–18. The most common cause for this 
deregulation is mutation in RAS/RAF family members, with mutant KRAS (40% of colorectal cancer cases) and 
BRAF (12% of cases) being the most prevalent16,18,19 Since MEK1/2 lies directly downstream of these mutations 
and uniquely phosphorylates ERK1/2, the MEK1/2 kinases have been identified as extremely attractive targets for 
therapeutic intervention.
Selumetinib is a potent, non-ATP competitive, small molecule inhibitor of MEK which has demonstrated sig-
nificant anti-tumour activity against colorectal cancer in vitro in cell line studies and in vivo, in mouse xenograft 
models20–22. The agent has also demonstrated a manageable toxicity profile and evidence of disease stabilisation 
in Phase I and II clinical trials23–27. However, although promising, these studies have revealed considerable var-
iability in response, with many tumours showing resistance23–27. Previous research aimed at stratifying patient 
sensitivity to the agent have primarily utilised human tumour cell lines, grown in vitro or as xenografts in nude 
mice. Not only have these approaches been poor at predicting outcomes in cancer patients but, they have also 
given inconsistent results with regards to the association between ras/raf mutations, pathway activation and drug 
sensitivity20,28,29. Clearly, alternative approaches are required for determining tumour sensitivity to this agent.
Here we developed an acute ex-vivo treatment protocol and demonstrated that target inhibition and pheno-
typic responses to Selumetinib could be quantified using this protocol. We also demonstrated a link between 
KRAS/BRAF mutational status and response to low dose Selumetinib, providing proof of principle that this 
approach can successfully identify genotype-phenotype association. We conclude that this methodology has the 
potential to identify patients that may benefit from treatment with MEK inhibitors and potentially other thera-
peutics and as such, warrants further clinical investigation.
Materials and Methods
Cell culture and reagents. Colon cancer cell lines RKO, HRT118, and HCT116 were obtained from ATCC/
ECACC and maintained as described30. Selumetinib (AstraZeneca) was dissolved in DMSO (10 mM stock) and 
cells treated as specified.
Acute ex vivo treatment of fresh colorectal tumour biopsies. Small colorectal tumour biopsies 
(1–2 cm2) were provided by a pathologist at the time of resection. Informed consent was obtained from all 
patients, full ethical approval was in place (Scottish Colorectal Cancer Genetic Susceptibility Study 3; Reference: 
11/SS/0109- approved by the multicentre research ethics committee) and all procedures were performed in 
accordance with the relevant regulations. Biopsies were immediately placed in culturing media (MEM supple-
mented with glutamine, penicillin/streptomycin and anti-mycotic/antibiotic mix (1:100, Sigma) and transferred 
to the lab (within 1 hour). Following two PBS washes, tumours were placed in a petri dish of culturing medium 
and dissected into 1–2 mm2 fragments. Fragments were washed again with fresh media then placed in wells of a 
96 well plate immersed in culturing medium containing 10% FCS and either 0, 0.1 or 3 µM Selumetinib. All sam-
ples had a final DMSO concentration of 0.03%. Two tumour fragments were treated per condition: one for immu-
nohistochemical analysis and one for protein extraction. Samples were incubated at 37 °C for the times specified.
Immunocytochemistry and immunohistochemistry. Immunocytochemistry and immunohistochem-
istry were carried out using standard protocols with antibodies against Ki-67 (1:100 DAKO) and active caspase-3 
(1:100, BD Biosciences) and fluorescently tagged secondary antibodies (Jackson Labs)31.
Imaging and analysis. Images were acquired as described31. The percentage of epithelial cells (defined by 
DAPI staining) positive for either Ki-67 or active caspase-3 was determined for five (immunohistochemistry) or 
ten (immunocytochemistry) random fields of view. In both cases, at least 190 cells per slide were analysed.
Western Blot analysis. Whole cell lysates were prepared from cell pellets and frozen tumour samples (with 
the aid a QIAGEN TissueLyser LT) using 1x Lysis Buffer as per the manufacturer’s instructions (Cell Signalling). 
Western blot analysis was performed on 30 µg of protein using antibodies to phosphorylated p44/42 MAPK 
(p-ERK1/2) (1:1000; Cell Signalling), p44/42 MAPK (ERK1/2) (1:1000; Cell Signalling) and β-actin (1:2000, 
Sigma), as previously described31.
Immunoblots were quantified using ImageJ software. Relative pERK1/2 intensity was determined by subtract-
ing background intensity from pERK1/2 band intensity then normalising this value using native ERK1/2 intensity 
and β-actin.
Mutation analysis. Mutational analysis was performed by AstraZeneca using a Roche Cobas system. KRAS 
codon 12 and 13 mutations and BRAFV600E were investigated.
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Statistical analysis. P values throughout were calculated using a two-tailed Student’s t-test unpaired with 
equal variance. For immunohistochemistry, P values were derived by comparing the data from the five fields of 
view from the untreated sample to the five fields of view from the Selumetinib treated sample. Pearsons corre-
lation coefficient (r2) was used to examine the relationship between fold decrease in proliferation in response to 
0.1 µM Selumetinib compared to 3 µM Selumetinib, for the 5 patients that showed a significant response only at 
the 0.1 µM dose (Subset 2).
Data availability. All data generated during this study, and all methods and materials utilised, are available 
upon request.
Results
Acute Selumetinib treatment inhibits MAPK/ERK signaling and induces a phenotypic 
response. We set out to determine whether an ex vivo treatment protocol could be used as a means of deter-
mining colorectal tumour sensitivity to Selumetinib. Firstly, we investigated the use of a number of methods that 
reportedly allow ex vivo growth of intestinal mucosa. However, we found that for all protocols tested, prolonged 
time in culture (>24 h) induced a significant increase in apoptosis and decrease in proliferation in colorectal 
tumour biopsies (Supplementary Table S1). Since ERK1/2 phosphorylation (which acts as a marker for MEK1/2 
activity) is inhibited within hours of Selumetinib treatment in clinical studies, we postulated that sensitivity could 
be measured using acute (less than 6 h) drug exposure23,24.
To test this principle, we firstly examined the pERK1/2 and phenotypic response to Selumetinib in colorec-
tal cancer cell lines that have known sensitivity differences when exposed to the agent for prolonged periods; 
RKO (BRAF mutant) and HRT18 (KRAS mutant) that are resistant and HCT116 (KRAS mutant) that is sensi-
tive20,32. The drug concentrations used in these studies were in keeping with those reported in patient plasma 
after Selumetinib treatment23. Figure 1a indicates that in all three cell lines tested, acute (0–6 h) exposure to 
pharmacologically relevant doses (0.1 or 3 µM) of Selumetinib induced a reduction in ERK1/2 phosphorylation. 
Notably, there was variability in this effect, with the reduction being most pronounced in the sensitive HCT116 
cells (Fig. 1a). Immunocytochemistry with antibodies to Ki-67 and active caspase-3 indicated that effects on pro-
liferation could not be detected within this time frame (data not shown). However, the pro-apoptotic effects of the 
agent were evident within 6 h of treatment in the sensitive HCT116 cell line (Fig. 1b).
These data suggested that it may be worthwhile exposing human tumours to the agent for short periods 
and so, we established the ex vivo treatment protocol outlined in Fig. 2a to examine responses to 0, 0.1 or 3 µM 
Selumetinib in time course studies. We found that the agent inhibited ERK1/2 phosphorylation within 1 h of 
treatment and showed little further decrease after 3 or 6 h (Fig. 2b). Significant changes in proliferation and apop-
tosis were also quantifiable within a 1 h time frame (Fig. 2c). Therefore, given that tumour samples were limited 
in size, we proceeded by focussing on a 1 h treatment protocol.
Acute treatment with Selumetinib inhibits MAPK/ERK signaling in human colorectal tumour 
explants. Tumours from 23 colorectal cancer patients were analysed using the optimised protocol. 
Non-cultured biopsies (time 0) acted as a baseline control. A summary of clinical, molecular and TNM staging 
data for the patient cohort is outlined in Table 1. The TNM stages equate to 2 stage IV, 8 stage III, 2 stage II and 4 
stage I tumours. Given the small numbers, we did not distinguish by stage in further studies.
Firstly, we used Western blot analysis with antibodies to phosphorylated and native ERK1/2, followed by 
ImageJ analysis of band intensity, to examine target inhibition. We found that collectively, short-term ex vivo 
exposure to Selumetinib caused a significant, dose-dependent decrease in relative ERK1/2 activity in all colorectal 
tumour biopsies (Fig. 3a). Individually, all tumours demonstrated significant target inhibition (>2 fold decrease 
in relative pERK1/2) when exposed to 3 µM Selumetinib. Target inhibition (>2 fold) was also observed in the 
majority (16/21) of tumours upon exposure to 0.1 µM Selumetinib (Fig. 3b and c). However, there were tumour 
specific differences in the degree of this effect (Fig. 3b and c).
In keeping with previous studies, we found that the variability in target inhibition at 0.1 µM Selumetinib 
was not related to basal ERK1/2 activity (Fig. 3d). It was also unrelated to the stress of being placed in culture. 
Indeed, we found that culturing had a minimal effect on the relative activity of the kinase (determined by com-
paring pERK1/2 levels at Time 0 and 0 µM) (Fig. 3e). Together, these data indicate that acute ex vivo exposure 
to Selumetinib induces a robust target inhibition in colorectal tumours and suggest that this may be a viable 
approach to examine tumour specific responses to treatment.
Acute ex vivo treatment with Selumetinib identifies tumour subsets with distinct phenotypic 
responses. Next, immunohistochemistry was used to determine whether differential proliferative (Ki-67) 
and apoptotic (caspase-3) responses to Selumetinib could be detected using acute drug treatment of small tumour 
biopsies. For each tissue section, the percentage of positive cells in five fields of view (>190 cells total) was quan-
tified. The average of these five fields was then calculated and used to determine the fold decrease in proliferation/
increase in apoptosis (compared to 0 µM) for each tumour at both doses (Fig. 4a and d). To determine whether a 
response was statistically significant, the % proliferation/apoptosis for the five fields of view for treated samples 
was compared to the five fields of view for 0 µM (using a students Ttest). Tumours showing a significant (p < 0.05) 
response at either dose were deemed sensitive. Examples of the raw data for sensitive and resistant tumours are 
shown (Fig. 4b and c).
These studies revealed that, taking both doses into account, ex vivo exposure to Selumetinib significantly 
(p < 0.05) inhibited proliferation in 11/23 (47.8%) tumours (Fig. 4a and b). Interestingly, within this group of 
sensitive tumours there were two distinct subsets. One subset (6/22) demonstrated a significant decrease at 3 µM 
but not necessarily 0.1 µM Selumetinib (Fig. 4a and b). In the other sensitive subset (5/22), a significant effect was 
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only apparent at the lower dose of the agent (Fig. 4a and b). Indeed, in this subset there was an inverse correlation 
(r2 = −0.66) between response at 0.1 µM and that at 3 µM. On analysis of apoptotic effects we found that in 3/23 
tumours there was a dose-dependent increase in apoptosis within an hour of Selumetinib treatment. However, 
in contrast to the anti-proliferative effect, this only reached significance at the higher dose (3 µM) of the agent 
(Fig. 4c and d).
We did consider that the acute phenotypic response to Selumetinib could be influenced by initial rates of pro-
liferation or apoptosis. However, we found that on a tumour by tumour basis, there was no association between 
basal proliferative or apoptotic state (determined by the Time 0 sample) and Selumetinib response (Supplemental 
Figs S1 and 2). We also considered that the acute phenotypic response may be influenced by the degree of 
catastrophe when the biopsy was placed in culture. However, again we found no association between maintenance 
of tissue integrity in culture (determined by comparing Time 0 to 0 µM) and the anti-proliferative/pro-apoptotic 
effects of Selumetinib (Supplemental Figs S1 and 2).
Taken together, these data suggested that acute ex vivo treatment of small tumour biopsies can identify the 
intrinsic phenotypic response to Selumetinib in colorectal tumours.
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Figure 1. Acute Selumetinib treatment inhibits MAPK/ERK signaling and induces a phenotypic response in a 
panel of colorectal cancer cell lines. (a,b) Colon cancer cell lines RKO (BRAF mutant), HRT118 (KRAS mutant) 
and HCT116 (KRAS mutant) were treated acutely (0–6 h) with 0, 0.1 or 3 µM Selumetinib. (a) Top: Western 
blot analysis shows effects on ERK1/2 activity, as indicated by p-ERK1/2 levels. Native ERK1/2 and actin act as 
controls. Cropped gels are shown. Full length versions are in Fig. S4a. Bottom: Quantification of western blots 
was carried out using ImageJ as described in materials and methods. Graphs show mean (+/− s.e.m) relative 
p-ERK1/2 intensity at each dose. N = 3. (b) Immunocytochemistry with antibodies to active caspase-3 was used 
to monitor apoptosis. Insert: Immunomicrograph showing an apoptotic (active caspase-3 positive) cell. The 
percentage of positive cells was determined in at least ten fields of view (minimum 200 cells). Graphs show the 
mean +/− s.e.m. N = 3.
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Acute treatment confirms that KRAS mutations confer increased sensitivity to the anti-proliferative 
effects of Selumetinib. Given the differential patient responses to Selumetinib in phase I clinical trials, efforts 
have been focussed on identifying predictive molecular biomarkers of sensitivity or resistance. Since our ex vivo culture 
system revealed sensitive and resistant tumours, we next determined whether it could be used to identify biomarkers 
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Figure 2. Short-term treatment of colorectal tumour biopsies ex vivo with Selumetinib. (a) Diagram depicting 
the short term ex vivo treatment protocol established. Figure adapted from O’Hara et al.36 with publishers 
permission. Three tumours were treated for 1, 3 and 6 h with 0–3uM Selumetinib. Data from one tumour (T10) 
is shown. (b) Western blot analysis, performed on whole tumour lysates with antibodies to p-ERK1/2, was 
used to analyse target inhibition in response to short term Selumetinib treatment. Native ERK1/2 and actin 
were used as controls. Cropped gels are shown. Full length versions are in Supplemental Fig. S4b. ImageJ was 
used to quantify relative P-ERK1/2 intensities as in Fig. 1. (c) Immunohistochemistry with antibodies to Ki-67 
and active caspase-3 was used to monitor effects of acute Selumetinib treatment on proliferation and apoptosis 
respectively. The percentage of positive cells in five independent areas of tumour was quantified as described 
in materials and methods. Top: representative immunomicrographs. Bottom: Mean (+/− s.e.m) of the 5 fields 
(minimum 190 cells) for the 1 h time point. P values were calculated by comparing the five data points for the 
treated sample to the five data points for the non-treated sample using a two tailed Student’s t-test.
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of response. Firstly, we assessed the association between phenotypic response and basal levels of p-ERK1/2, or inhi-
bition of ERK1/2 activity. We would predict that tumours with high basal pERK1/2 would be more dependent on 
the RAF/MEK/ERK pathway for growth and survival, and hence, more sensitive to the MEK inhibitor. However, we 
found that tumours that showed high basal levels of pERK, such as tumour 11, showed no phenotypic response to the 
agent (Figs 3d and 4c). Conversely, tumours such as T5, which showed a significant, dose-dependent, anti-proliferative 
response to Selumetinib, had low basal pERK1/2 (Figs 3d and 4b). Indeed, when basal pERK1/2 was compared to fold 
response at 0.1 or 3 µM Selumetinib, there was no correlation. Similarly, there was no correlation between degree of 
target inhibition and phenotypic response (see tumour 14 for example (Figs 3 and 4)).
Tumours with mutations in the MEK/ERK pathway have been found to be particularly sensitive to Selumetinib 
therapy. However, some disparate results have been reported20,32–34. Therefore, we next determined whether our 
model could be used to explore genotype, phenotype relationships. Firstly, our panel of tumours were evaluated 
for the most common KRAS (codon 12 and 13) and BRAF (V600E) mutations. Mutations in PIK3CA, which are 
reported to increase resistance to MEK inhibition, were also evaluated19 (Table 1). From the 22 samples analysed, 
five KRAS (codon 12 and 13), two BRAF(V600E) and 2 PIK3CA mutants were identified, including one tumour 
with a BRAF and PIK3CA mutation (supporting Fig. 3).
First, we compared basal levels of p-ERK1/2 and found that there was no significant difference between wild 
type and KRAS/BRAF mutant tumours, either when mutants were analysed collectively (all mutations in the 
pathway) or when mutations were considered individually (i.e KRAS codon 12/13 and BRAFV600E) (Fig. 5a and 
Supplemental Fig. S3a). There was also no significant difference in the basal rates of proliferation or apoptosis 
in the two populations (Fig. 5b,c and Supplemental Fig. S3b and c). Upon Selumetinib treatment, we found that 
target inhibition and the induction of apoptosis did not differ between wild type and KRAS mutant tumours 
(Fig. 5d and e). However, the agent had dramatically different effects on proliferation in the two populations. We 
found that Selumetinib induced a significant reduction in proliferation specifically in KRAS (codon 12 and 13) 
mutant tumours (Fig. 5f). Furthermore, this reduction was particularly pronounced at the lower dose (0.1 µM 
(p = 0.02) vs 3 µM (P = 0.05)) of the compound (Fig. 5f). In fact, 3 of the 5 tumours (60%) that showed a sig-
nificant anti-proliferative response uniquely at 0.1 µM Selumetinib (Subset 2) had KRAS or BRAF mutations 
(Fig. 5g). In contrast, mutations were only detected in 2 of the 12 (16.7%) resistant tumours (Fig. 5g).
Collectively, these data suggest that tumours with KRAS mutations have increased sensitivity to the 
anti-proliferative effects of Selumetinib. They also provide proof of principle that this model system can detect 
specific anti-proliferative effects and may be used to establish associations between genetic biomarkers and phe-
notypic responses to drug treatment.
Sex (N = 23)
Males 15 (65%)
Females 8 (35%)
Age
Median 69
Range 39–80
TNM staging (N = 16)
T2 4 (25%)
T3 10 (62.5%)
T4 2 (12.5%)
N0 6 (37.5%)
N1 7 (43.75%)
N2 3 (18.75%)
M0 14 (87.5%)
M2 2 (12.5%)
Site (N = 16)
Colon 10 (62.5%)
Rectum 6 (37.5%)
KRAS Status (N = 22)
Wild Type 17 (77.3%)
Codon 12/13 mutant 5 (26.7%)
BRAF Status (N = 22)
Wild Type 20 (90.9%)
V600E Mutant 2 (9.1%)
PI3K status
Wild Type 20 (90.9%)
Mutant 2 (9.1%)
Table 1. Characteristics of patient cohort.
www.nature.com/scientificreports/
7SCIENtIfIC REPORtS | 7: 12020  | DOI:10.1038/s41598-017-12222-9
Discussion
Targeted therapy, based on the unique biological characteristics of each individual tumour, is revolutionizing 
treatment options for cancer patients. However, to realise the full clinical potential of this approach, better tools 
are required for identifying biologically discreet subpopulations of patients, so that they can be stratified to cor-
rect therapeutic regimes. Here we explored the use of acute ex-vivo treatment of small, tumour biopsies as a novel 
method for identifying colorectal tumour sensitivity to specific therapeutics. The MEK inhibitor, Selumetinib, 
was used to test the efficacy of the approach.
Using the short term ex-vivo treatment protocol we established that: 1) 3 µM of Selumetinib inhibits pERK1/2 
phosphorylation in all tumours and the effect is independent of whether or not tumours harbour a KRAS or BRAF 
mutation. 2) Low dose Selumetinib induced a significant reduction in Ki-67 staining in 5/23 (22%) tumours. 3) 
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Figure 3. Effects of acute Selumetinib treatment on ERK1/2 activity in colorectal tumour biopsies. (a–e) 
Twenty three tumour biopsies were treated for 1 h ex vivo with 0, 0.1 or 3 µM Selumetinib, as outlined in 
Fig. 2a. Western blot analysis with antibodies to phosphorylated ERK1/2 (pERK1/2), native ERK1/2 and actin 
determined effects of the agent on relative ERK activity. A time 0 control was also analysed to gain information 
on baseline levels of active kinase. Quantification of western blots was carried out using ImageJ as described in 
materials and methods. (a) Graph showing mean (+/− s.e.m) relative p-ERK1/2 intensity at each dose N = 21. 
(b) Tumours were stratified based on fold decrease in relative pERK1/2 at 0.1 µM Selumetinib (compared to 
0 µM). Stratified tumours were renumbered 1 to 23. ND = non-detectable at all doses. Those tumours mutant 
for KRAS or BRAF are highlighted in bold (see Fig. 5) (c) Example immunoblots. T3 and T14 have a > 2 
fold decease in relative p-ERK1/2 levels following 1 h treatment with 0.1uM Selumetinib. T20 and T21 show 
minimal effect at this dose. Cropped gels are shown. Full length versions are in Supplemental Fig. S4c (d) 
Relative p-ERK1/2 levels at time 0 (basal) is shown for each tumour. (e) Effects of culture on relative p-ERK1/2 
activity was determined by comparing intensity at T0 (basal) to 0uM (1 h culture) Mean of 23 samples (+/− 
s.e.m.) is shown.
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Figure 4. Proliferation and apoptosis in colorectal tumour biopsies following acute Selumetinib treatment. 
(a–d) Tumour biopsies from 23 colorectal cancer patients were treated with 0, 0.1 or 3 µM Selumetinib for 
1 h as detailed in Fig. 2a. Immunohistochemistry was performed on formalin fixed, paraffin embedded tissue 
with antibodies to active caspase-3 (marker for apoptotic cells) and Ki-67 (marker for proliferating cells). 
The percentage of positive cells was quantified in five independent areas of tumour for each sample and each 
treatment point (as in Fig. 2). Significance was determined by comparing the five data points for the treated 
sample to the five data points for the non-treated sample using a two tailed Student’s t-test. (a and d) Graphs 
showing fold change in proliferation (a) and apoptosis (d) for all tumours at both doses (compared to 0 µM). 
*P < 0.05 when significance was determined from raw data as described above. Those tumours mutant for 
KRAS or BRAF are highlighted in bold (see Fig. 5). (b,c) Graphs showing the mean percentage of proliferating 
(b) or apoptosing (c) cells in the 5 independent fields (+/− s.e.m) for representative sensitive and resistant 
tumours.
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Figure 5. Influence of KRAS mutational status on ERK1/2 activity and tumour sensitivity to Selumetinib. (a–f) 
Twenty two tumours were analysed for codon 12/13 mutations in KRAS, and for BRAFV600E mutations. (a–c) 
Graphs showing mean (+/− s.e.m) basal (T0) levels of (a) p-ERK1/2, (b) proliferation and (c) apoptosis in 
wild type and KRAS/BRAF mutant tumours collectively. See also Supporting Fig. 3. (d) Fold change in relative 
p-ERK1/2 activity in wild type and KRAS mutant tumours. (e and f) Mean (+/− s.e.m, N = 22) percentage (e) 
apoptosis and (f) proliferation in untreated (0 µm) and treated (0.1–3 µM Selumetinib) wild type and KRAS 
mutant tumours. (g) Subsets 1, 2 and 3 refer to subsets 1, 2 and 3 outlined in Fig. 4. Subset 1-A significant 
decrease in proliferation in response to 3 µM Selumetinib but not necessarily 0.1 µM. Subset 2- Significant 
response only at 0.1 µM Selumetinib. Subset 3: No significant response.
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the phenotypic responses to the agent were independent of the magnitude of target inhibition, and 4) KRAS 
mutant tumours were particularly sensitive to the anti-proliferative effects of Selumetinib. These findings are 
consistent with those of a phase I clinical study where it was shown that 5/20 biopsies of human tumours demon-
strated a 2 fold reduction in Ki-67 staining after 7 days Selumetinib treatment, that all biopsies demonstrated a 
reduction in pERK1/2 staining, that wild-type and KRAS/BRAF mutants showed similar levels of target inhibition 
and that mutant tumours were more sensitive to the growth inhibitory effects of the agent23. Using xenografts of 
patient derived metastatic colorectal cancer grown in mice, Migliardi et al., also found that Selumetinib inhib-
ited pERK1/2 activity in all cancers and caused disease stabilisation in 27%29. These similarities suggest that our 
ex vivo model system may have the potential to reveal clinical responses to MEK inhibitors. It would now be 
extremely interesting to undertake clinical trials alongside ex vivo treatment in order to fully assess this approach.
Our data indicate that mutations in the MAPK/ERK pathway are associated with an enhanced 
anti-proliferative response to low dose Selumetinib. This result was extremely encouraging with regards to the 
model system as it suggested the phenotypic effects we observed at low doses of the agent are valid, and that this 
approach has the potential to identify genotype-phenotype relationships. However, these data are in contrast to 
a number of studies in the field, which demonstrate the phenotypic response to Selumetinib is independent of 
the mutational status of this pathway32,34. One possibility for the discrepancy is the dose of the agent utilised. We 
found that the relationship between genotype and phenotype was particularly evident at 0.1 µM Selumetinib, 
which is a tenth of the maximum tolerated dose in humans and is a lower dose than is generally used in in vitro 
studies. Since resistance to MEK inhibitors in RAS/RAF mutated tumours has been attributed to negative feed-
back mechanisms, it is possible that at this lower dose, MEK inhibitors show more specificity for their target and 
are less likely to activate these feedback mechanisms. Our ex-vivo methodology would be an ideal platform to 
interrogate such adaptive signalling further.
In this study we used a MEK inhibitor as a model therapeutic to test our ex vivo methodology. However, the 
protocol we established has the potential to reveal information regarding response to other agents. Indeed, we 
have used this protocol to examine tumour response to low doses of the chemopreventative/therapeutic agent, 
aspirin. Our cell line studies had demonstrated that aspirin causes an increase in levels of the NF-κB suppressor, 
COMMD135. Using the described ex vivo protocol with patient tumour biopsies, we could show that aspirin also 
caused increased COMMD1 in 3/4 colorectal tumours, again potentially identifying patients that would benefit 
for aspirin therapy36. Together, these data suggest that this approach has broad application.
Although other groups have published protocols for assessing tumour response to therapeutics ex vivo, these 
generally involve tumour manipulation (for example by sectioning or xenograft growth) prior to ex vivo cul-
ture14,15. The advantage of our method is that it does not require pre-manipulation, enabling the use of very fresh, 
extremely small tumour biopsies. As we have shown drug response (Selumetinib and aspirin) can be quantified 
after acute treatment using this ex vivo culture protocol, this methodology could be ideal as a fast, cost effective 
means of identifying patients that would benefit from Selumetinib or other therapies following surgical resec-
tion of primary tumour. Since this protocol does not allow long term growth of tumours, it could be argued 
that patients who respond with delayed kinetics may be overlooked. The question of whether the kinetics of the 
response influences the phenotypic outcome is interesting and should be addressed in clinical trials undertaken 
alongside ex vivo treatment.
In summary, we show that acute ex vivo treatment of small biopsies of human colorectal tumours has consid-
erable potential as means to reveal patient specific responses to MEK inhibitors and other therapeutic agents and 
to identify markers of response. We conclude that this approach warrants further investigation.
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